<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00895193</url>
  </required_header>
  <id_info>
    <org_study_id>11627</org_study_id>
    <nct_id>NCT00895193</nct_id>
  </id_info>
  <brief_title>Alternative Options to Minimize Niacin-Induced Flushing</brief_title>
  <official_title>Alternative Options to Minimize Niacin-Induced Flushing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrick Moriarty, MD, FACP, FACC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Niacin (Vitamin B3) is known to effectively and safely treat hypercholesterolemia. However,
      use of niacin is limited due to incidents of flushing which limits its acceptability. Some
      information suggests that applesauce can reduce the incidence and severity of flushing. The
      apple pectin in particular is thought to be the ingredient that affects this reaction. To
      determine if the apple pectin does affect flushing from niacin, the investigators will study
      the affects of isolated apple pectin in pill form. The investigators plan on recruiting 100
      patients, and giving them 1000 mg of Niacin to induce flushing. Patients will be divided into
      4 treatment groups and receive either pectin, aspirin, a combination of both, or placebo.
      Incidents and severity of flushing will be monitored for up to 6 hours post Niacin ingestion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Flushing</measure>
    <time_frame>Hourly for 6 hours on day of dosing</time_frame>
    <description>Flushing assessment performed hourly for 6 hours after niacin administration. Incidence of flushing based on if the participant experience any niacin-induced flushing during the 6 hour period after dosing. Represents # of participants that experienced event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Flushing</measure>
    <time_frame>6 hours after dosing</time_frame>
    <description>The time it took, in minutes, for a participant to experience any flushing. Time to flush for individuals that did not experience flushing within 6 hours was set to 360 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Flushing</measure>
    <time_frame>6 hours after dosing</time_frame>
    <description>The amount of time, in minutes, that flushing lasted. Duration of individuals without experience flushing within 6 hours was set to 0 minutes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Flushing Severity Score</measure>
    <time_frame>6 hours after dosing</time_frame>
    <description>Flushing assessment performed hourly for six hours. Assessment of severity done using the validated visual analog scale (VAS) flushing assessment tool (FAST). Severity rated using a VAS from mild (1-3), moderate (4-6), severe (7-9) to very severe (10). The maximum severity score was the maximum severity score of each individual during the 6 hours of monitoring time period.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Flushing</condition>
  <arm_group>
    <arm_group_label>Apple-pectin 2000mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regular Non-enteric coated aspirin 325mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apple pectin + aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Apple pectin</intervention_name>
    <description>Apple pectin 2000mg</description>
    <arm_group_label>Apple-pectin 2000mg</arm_group_label>
    <arm_group_label>Apple pectin + aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 325 mg</intervention_name>
    <description>Aspirin 325 mg</description>
    <arm_group_label>Regular Non-enteric coated aspirin 325mg</arm_group_label>
    <arm_group_label>Apple pectin + aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An adult between 21 and 70 years of age.

          -  Male or female (If female must be postmenopausal for at least 1 year, surgically
             sterile or using an effective form of contraception).

          -  Able to speak and read English.

          -  Willing to comply with study specific instructions, and complete all study procedures
             according to protocol.

          -  Able to understand study rationale and sign informed consent.

        Exclusion Criteria:

          -  Females of child-bearing potential not using acceptable method of contraception and
             perimenopausal females.

          -  History of gout

          -  History of diabetes mellitus

          -  History of coronary heart disease

          -  History of, or currently experiencing, renal disease including, but not limited to,
             renal insufficiency, nephrolithiasis or chronic renal failure.

          -  History of, or currently experiencing, major chronic gastrointestinal condition
             including gallbladder disease, liver disease and peptic ulcer disease

          -  Known sensitivity to niacin, Aspirin or nonsteroidal anti-inflammatory agents (NSAIDs)

          -  History of migraine or cluster headaches

          -  Currently using antihistamines, aspirin or NSAIDS on a consistent basis

          -  Presence or history of any medical or psychosocial condition that, in the opinion of
             the investigator, would limit the patient's successful participation or would
             compromise the patient's safe participation.

          -  Lab abnormalities at screening, including but not limited to elevated liver enzymes or
             blood sugar levels that might indicate additional risk to the patient's continued
             participation.

          -  Currently taking medication that might be contraindicated with the study drug or
             Niacin or study procedures (including Niacin, lipid-lowering drugs, chronic aspirin or
             laxative use).

          -  Clinically significant finding from physical exam that would affect the patient's safe
             participation or completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Moriarty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2009</study_first_submitted>
  <study_first_submitted_qc>May 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2009</study_first_posted>
  <results_first_submitted>February 3, 2014</results_first_submitted>
  <results_first_submitted_qc>February 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2014</results_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Patrick Moriarty, MD, FACP, FACC</investigator_full_name>
    <investigator_title>Director, Clinical Pharmacology</investigator_title>
  </responsible_party>
  <keyword>Niacin</keyword>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Flushing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Flushing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Pectin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Initial screening occurred over the telephone. Subjects that met preliminary study criteria were scheduled for a screening visit. Recruitment was conducted at the University of Kansas Medical Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Apple-pectin 2000mg</title>
          <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="P2">
          <title>Regular Non-enteric Coated Aspirin 325mg</title>
          <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="P3">
          <title>Apple Pectin + Aspirin</title>
          <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="P4">
          <title>Placebo Comparator</title>
          <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Apple-pectin 2000mg</title>
          <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="B2">
          <title>Regular Non-enteric Coated Aspirin 325mg</title>
          <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="B3">
          <title>Apple Pectin + Aspirin</title>
          <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="B4">
          <title>Placebo Comparator</title>
          <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="25"/>
            <count group_id="B5" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" spread="11.5"/>
                    <measurement group_id="B2" value="40" spread="13.3"/>
                    <measurement group_id="B3" value="40" spread="12.3"/>
                    <measurement group_id="B4" value="38" spread="12.7"/>
                    <measurement group_id="B5" value="38.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="5.5"/>
                    <measurement group_id="B2" value="27" spread="6.2"/>
                    <measurement group_id="B3" value="26" spread="5.3"/>
                    <measurement group_id="B4" value="26" spread="5.0"/>
                    <measurement group_id="B5" value="26.4" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="6.1"/>
                    <measurement group_id="B2" value="36" spread="6.3"/>
                    <measurement group_id="B3" value="34" spread="5.0"/>
                    <measurement group_id="B4" value="35" spread="5.3"/>
                    <measurement group_id="B5" value="35" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Flushing</title>
        <description>Flushing assessment performed hourly for 6 hours after niacin administration. Incidence of flushing based on if the participant experience any niacin-induced flushing during the 6 hour period after dosing. Represents # of participants that experienced event.</description>
        <time_frame>Hourly for 6 hours on day of dosing</time_frame>
        <population>This was a single-site, randomized trial, 4-arm parallel design trial. Each arm consisted of 25 randomized participants. All participants completed the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Apple-pectin 2000mg</title>
            <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O2">
            <title>Regular Non-enteric Coated Aspirin 325mg</title>
            <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O3">
            <title>Apple Pectin + Aspirin</title>
            <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator</title>
            <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Flushing</title>
          <description>Flushing assessment performed hourly for 6 hours after niacin administration. Incidence of flushing based on if the participant experience any niacin-induced flushing during the 6 hour period after dosing. Represents # of participants that experienced event.</description>
          <population>This was a single-site, randomized trial, 4-arm parallel design trial. Each arm consisted of 25 randomized participants. All participants completed the study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Flushing</title>
        <description>The time it took, in minutes, for a participant to experience any flushing. Time to flush for individuals that did not experience flushing within 6 hours was set to 360 minutes.</description>
        <time_frame>6 hours after dosing</time_frame>
        <population>All participants randomized to the study completed the study. Each arm had 25 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apple-pectin 2000mg</title>
            <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O2">
            <title>Regular Non-enteric Coated Aspirin 325mg</title>
            <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O3">
            <title>Apple Pectin + Aspirin</title>
            <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator</title>
            <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Flushing</title>
          <description>The time it took, in minutes, for a participant to experience any flushing. Time to flush for individuals that did not experience flushing within 6 hours was set to 360 minutes.</description>
          <population>All participants randomized to the study completed the study. Each arm had 25 participants.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.4" spread="51.7"/>
                    <measurement group_id="O2" value="48.7" spread="33.8"/>
                    <measurement group_id="O3" value="58.8" spread="42.5"/>
                    <measurement group_id="O4" value="58.1" spread="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Flushing</title>
        <description>The amount of time, in minutes, that flushing lasted. Duration of individuals without experience flushing within 6 hours was set to 0 minutes.</description>
        <time_frame>6 hours after dosing</time_frame>
        <population>All participants randomized to the study completed the study. Each arm had 25 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apple-pectin 2000mg</title>
            <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O2">
            <title>Regular Non-enteric Coated Aspirin 325mg</title>
            <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O3">
            <title>Apple Pectin + Aspirin</title>
            <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator</title>
            <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Flushing</title>
          <description>The amount of time, in minutes, that flushing lasted. Duration of individuals without experience flushing within 6 hours was set to 0 minutes.</description>
          <population>All participants randomized to the study completed the study. Each arm had 25 participants.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="35.7"/>
                    <measurement group_id="O2" value="52.7" spread="53.5"/>
                    <measurement group_id="O3" value="58.3" spread="40.2"/>
                    <measurement group_id="O4" value="88" spread="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Flushing Severity Score</title>
        <description>Flushing assessment performed hourly for six hours. Assessment of severity done using the validated visual analog scale (VAS) flushing assessment tool (FAST). Severity rated using a VAS from mild (1-3), moderate (4-6), severe (7-9) to very severe (10). The maximum severity score was the maximum severity score of each individual during the 6 hours of monitoring time period.</description>
        <time_frame>6 hours after dosing</time_frame>
        <population>All participants randomized to the study completed the study. Each arm had 25 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Apple-pectin 2000mg</title>
            <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O2">
            <title>Regular Non-enteric Coated Aspirin 325mg</title>
            <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O3">
            <title>Apple Pectin + Aspirin</title>
            <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
          <group group_id="O4">
            <title>Placebo Comparator</title>
            <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Flushing Severity Score</title>
          <description>Flushing assessment performed hourly for six hours. Assessment of severity done using the validated visual analog scale (VAS) flushing assessment tool (FAST). Severity rated using a VAS from mild (1-3), moderate (4-6), severe (7-9) to very severe (10). The maximum severity score was the maximum severity score of each individual during the 6 hours of monitoring time period.</description>
          <population>All participants randomized to the study completed the study. Each arm had 25 participants.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="2.7"/>
                    <measurement group_id="O2" value="2.8" spread="2.6"/>
                    <measurement group_id="O3" value="3.3" spread="2.5"/>
                    <measurement group_id="O4" value="3.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Apple-pectin 2000mg</title>
          <description>Participant receives Apple pectin 2000mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="E2">
          <title>Regular Non-enteric Coated Aspirin 325mg</title>
          <description>Participant receives aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="E3">
          <title>Apple Pectin + Aspirin</title>
          <description>Participant receives apple pectin 2000mg and aspirin 325 mg 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
        <group group_id="E4">
          <title>Placebo Comparator</title>
          <description>Participant receives placebo 30 minutes prior to a one-time 1000mg dose of extended-release niacin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include: pilot design, small sample size, short duration of a one-time niacin dose, utilization of only one niacin formulation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Julie-Ann Dutton, MS, RD</name_or_title>
      <organization>University of Kansas Medical Center</organization>
      <phone>(913) 588-4064</phone>
      <email>jdutton@kumc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

